LRP1B suppresses HCC progression through the NCSTN/PI3K/AKT signaling axis and affects doxorubicin resistance

LRP1B suppresses HCC progression through the NCSTN/PI3K/AKT signaling axis and affects doxorubicin resistance

Accumulating evidence supports the association of somatic mutations with tumor occurrence and development. We aimed to identify somatic mutations with important implications in hepatocellular carcinoma (HCC) and explore their possible mechanisms. The gene mutation profiles of HCC patients were asses...

Full description

Bibliographic Details
Main Authors: Xiangyu Zhai, Zhijia Xia, Gang Du, Xinlu Zhang, Tong Xia, Delin Ma, Xiaosong Li, Bin Jin, Hao Zhang
Format: Article
Language:English
Published: KeAi Communications Co., Ltd. 2023-09-01
Series:Genes and Diseases
Subjects:
Doxorubicin
Hepatocellular carcinoma
LRP1B
PI3K/AKT pathway
Tumor mutation burden
Online Access:http://www.sciencedirect.com/science/article/pii/S2352304222002938

Internet

http://www.sciencedirect.com/science/article/pii/S2352304222002938

Similar Items